Suppr超能文献

人体对口服益生菌唾液链球菌 BLIS K12 的全身免疫反应。

Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12.

机构信息

Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.

Blis Technologies, Dunedin, New Zealand.

出版信息

Probiotics Antimicrob Proteins. 2021 Dec;13(6):1521-1529. doi: 10.1007/s12602-021-09822-3. Epub 2021 Jul 19.

Abstract

Streptococcus salivarius K12 is an oral probiotic known to contribute to protection against oral pathogenic bacteria in humans. Studies of immune responses to S. salivarius K12 have focused on the oral cavity, and systemic immune responses have not yet been reported. The aim of this study was to identify acute systemic immune responses to the commercial product, S. salivarius BLIS K12, in a double-blinded, placebo-controlled human clinical trial. It was hypothesised that consumption of S. salivarius BLIS K12 would induce an anti-inflammatory response and a decrease in pro-inflammatory cytokines. Blood samples were obtained from participants prior to a single dose of S. salivarius BLIS K12 or a placebo and then secondary blood samples were obtained 24 h and 7 days post-consumption. Samples were analysed using multi-parametric flow cytometry, to quantify immune cell frequency changes, and by a LEGENDplex assay of human inflammatory cytokines. Consumption of S. salivarius BLIS K12 was associated with increased levels of IL-8 at 24 h. The frequency of Tregs increased in samples taken 7 days after probiotic consumption, and IL-10 concentrations were higher at 7 days than 24 h after consumption. There was no difference in the frequency and/or activation of CD4 T cells, CD8 T cells, B cells and NK cells. Interestingly, there was an increase in IL-12, 7 days after the consumption of S. salivarius BLIS K12. Collectively, this research demonstrates that ingestion of the probiotic S. salivarius K12 can induce changes in the systemic immune response. The implications of the generation and type of immune response warrant further study to determine potential health benefits.

摘要

唾液链球菌 K12 是一种口腔益生菌,已知可有助于防止人类口腔中的致病细菌。对唾液链球菌 K12 的免疫反应研究集中在口腔,而系统免疫反应尚未报道。本研究旨在通过双盲、安慰剂对照的人体临床试验,确定商业产品唾液链球菌 BLIS K12 引起的急性全身免疫反应。研究假设,摄入唾液链球菌 BLIS K12 会引起抗炎反应和促炎细胞因子减少。在单次摄入唾液链球菌 BLIS K12 或安慰剂之前,从参与者中采集血样,然后在摄入后 24 小时和 7 天采集二次血样。使用多参数流式细胞术分析样本,以定量免疫细胞频率变化,并通过人类炎症细胞因子的 LEGENDplex 测定法进行分析。摄入唾液链球菌 BLIS K12 与 24 小时时的 IL-8 水平升高有关。在益生菌摄入 7 天后,Treg 的频率增加,且摄入后 7 天的 IL-10 浓度高于 24 小时。CD4 T 细胞、CD8 T 细胞、B 细胞和 NK 细胞的频率和/或激活没有差异。有趣的是,在摄入唾液链球菌 BLIS K12 7 天后,IL-12 增加。总的来说,这项研究表明,摄入益生菌唾液链球菌 K12 可以诱导全身免疫反应的变化。产生和类型的免疫反应的影响需要进一步研究,以确定潜在的健康益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验